300149 睿智醫藥
按盤價 
6.700 -0.010 (-0.149%)
6.700 -0.010 (-0.149%) | 2024/09 - 九個月 人民幣(K¥) | 與去年同期 比較 | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | 2020/12 人民幣(K¥) | ||
| 營業總收入 | 718,526 | -15.09% | 1,138,366 | 1,326,584 | 1,690,678 | 1,481,592 | |
| 減：營業總成本 | 774,216 | -11.99% | 1,198,435 | 1,409,047 | 1,699,260 | 1,330,229 | |
| 其中:營業成本 | 580,392 | -8.72% | 843,125 | 989,329 | 1,154,908 | 913,918 | |
| 財務費用 | 8,106 | 49.02% | 14,025 | 11,814 | 82,351 | 58,027 | |
| 資產減值損失 | (13,628) | 379.07% | (877,870) | (550,029) | (371,485) | (43,229) | |
| 公允價值變動收益 | 2 | -100.45% | 0 | (43) | 63 | -- | |
| 投資收益 | 7,302 | -28.86% | (922) | 1,391,040 | 10,990 | 94,255 | |
| 其中：對聯營企業和合營企業的投資收益 | 7,073 | -27.09% | (1,531) | (317) | 16 | 17,823 | |
| 營業利潤 | (66,558) | 168.29% | (936,364) | 747,525 | (355,403) | 199,422 | |
| 利潤總額 | (67,039) | 173.02% | (939,766) | 728,762 | (361,030) | 193,499 | |
| 減：所得稅費用 | (5,256) | -176.02% | (22,827) | 366,344 | 41,067 | 39,470 | |
| 淨利潤 | (61,782) | 96.33% | (916,939) | 362,418 | (402,097) | 154,029 | |
| 減：非控股權益 | (115) | -20.83% | (186) | (207) | 148 | (521) | |
| 股東淨利潤 | (61,667) | 96.88% | (916,753) | 362,625 | (402,245) | 154,550 | |
市場價值指標 | |||||||
| 每股收益 (元) * | -0.120 | 100.00% | -1.840 | 0.730 | -0.810 | 0.310 | |
| 每股派息 (元) * | -- | -- | -- | -- | -- | 0.070 | |
| 每股淨資產 (元) * | 2.732 | -41.40% | 2.924 | 4.725 | 3.931 | 4.858 | |
| 審計意見 # | -- | 标准的无保留意见 | 标准的无保留意见 | 带持续经营重大不确定性段落的无保留意见 | -- | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 報價延遲最少15分鐘，資料更新時間為 27/12/2024 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
